

## EUROGIN 2010

**CERVICAL CANCER PREVENTION:  
20 YEARS OF PROGRESS AND A PATH TO THE FUTURE**  
Monte-Carlo (Monaco) – Grimaldi Forum  
February 17-20, 2010

### PRELIMINARY PROGRAM

#### HONORARY PRESIDENTS:

**E. Franco (Canada) – C. Meijer (The Netherlands)**

#### Chairman of the Scientific Committee:

**J. Monsonego (France)**

## TRAINING COURSE

**Wednesday, 17 February**

The training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting educators in the health field. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies and prophylactic HPV vaccines.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

### **TC1 Basic research and fundamentals**

**8:30 – 10:30 Chair: X. Bosch (Spain) / S. Franceschi (France)**

- |   |               |        |
|---|---------------|--------|
| • Updating viral molecular biology and pathogenesis   | J. Doorbar    | UK     |
| • The burden of related cancers   | J. Smith      | USA    |
| • The burden of associated CIN diseases   | G. Clifford   | France |
| • HPV distribution in normal conditions and diseases of the ano-genital tract (cervix excluded) | S. Franceschi | France |
| • Epidemiology and transmission of HPV infection  | X. Bosch      | Spain  |
| • Discussion  |               |        |

**10:30 – 11:00 Coffee Break**

### **TC2 Screening**

**11:00 – 12:30 Chair: J. Cuzick (UK) / W. Kinney (USA)**

- |   |             |             |
|---|-------------|-------------|
| • LBC: the real picture                                       | A. Herbert  | UK          |
| • HPV/Pap triage in routine primary cervical cancer screening | C. Meijer   | Netherlands |
| • Squamous precursor lesions: two-tiered terminology          | K. Syrjänen | Finland     |
| • New strategies of cervical cancer screening                 | J. Cuzick   | UK          |
| • Discussion  |             |             |

### TC3 Management

14:00 – 15:30 Chair: A. Ferenczy (Canada) / A. Singer (UK)

- |  |             |             |
|--|-------------|-------------|
| • Accuracy, limitations of colposcopic performance                                   | M. Stoler   | USA         |
| • Glandular lesions as per TBS 2006  | R. Kurman   | USA         |
| • Treatment of genital warts: from traditional to botanical and "off-label" products | A. Ferenczy | Canada      |
| • HPV-related diseases and mimics  | M. Sideri   | Italy       |
| • VIN1 versus VIN2/3: a two-disease concept  | R. Jones    | New Zealand |
| • Therapeutic HPV vaccines: current data   | L. Gissmann | Germany     |
| • Discussion   |             |             |

15:30 – 16:00 Coffee break

### TC4 Vaccination

16:00 – 17:30 Chair: E. Franco (Canada) / J. Paavonen (Finland)

- |   |               |           |
|---|---------------|-----------|
| • Long term vaccine efficacy by age groups          | S. Garland    | Australia |
| • Males vaccination – latest data                   | J. Palefsky   | USA       |
| • Impact on screening, diagnosis and treatment      | E. Franco     | Canada    |
| • Innovative approaches in vaccination surveillance | C. Wheeler    | USA       |
| • Correlates of immune protection                   | M. Stanley    | UK        |
| • Issues related to best age to vaccinate           | A.B. Moscicki | USA       |
| • Advocacy: who, where and how to?                  | P. Morton     | Ireland   |
| • Discussion  |               |           |

---

## OPENING CEREMONY

Wednesday, 17 February

19:15 – 20:30 **EUROGIN 2010**  
**OPENING LECTURES**

- |   |  |                       |
|---|--|-----------------------|
| • EUROGIN: 20 year history in training health professionals                 | E. Franco<br>C. Meijer<br>Honorary Presidents        | Canada<br>Netherlands |
| • The challenge of public education   | J. Monsonego<br>Chairman of the Scientific Committee | France                |
| • Natural history and carcinogenesis of cervical cancer: the global picture | H. Zur Hausen<br>Nobel Prize for Medicine 2008       | Germany               |

## WELCOME COCKTAIL

20:30 – 21:30

---

# PLENARY SESSIONS

These sessions include keynote lectures giving a broad overview of the essential issues of cervical cancer prevention by the most prominent experts in their respective field.

## PLENARY SESSION 1

Thursday, 18 February

**14:00 – 15:30 Viral molecular biology and pathogenesis: the state of the art**

**Chair: M. Favre (France) / A.B. Moscicki (USA)**

Lecture	• The biology of HPV infection	J. Doorbar	UK	20'
	• Cellular networks targeted by early proteins and oncogenic potential	Y. Jacob	France	15'
	• Genetic rearrangements and transcriptional profiling in HPV associated cancers	P. Snijders	Netherlands	15'
	• Host Epigenetic changes in cervical precancers and cancers	N. Wentzensen	USA	15'
	• Epigenetic regulation of HPV genome during infection and cell transformation	M. von Knebel-Doeberitz	Germany	15'
	• Genetic predisposition to HPV infection	M. Favre	France	15'

## PLENARY SESSION 2

Thursday, 18 February

**15:30 – 17:00 Global prevention of cervical cancer – new paradigms for developed and developing countries**

**Chair: R. Sankaranarayanan (France) / M. Kane (USA)**

Lecture	• Integrating screening and vaccination programs	H. Lawson	USA
	• Cervical cancer risk stratification	P. Castle	UK
	• Preventing cervical cancer in sub-Saharan Africa: challenges and opportunities	L. Denny	South Africa
	• Cervical cancer prevention policies in central and South America: promise and problems	S. Luciani	USA
	• Cervical cancer control in Asia Pacific: current efforts and future prospects	R. Sankaranarayanan	France
	• Issues around uptake of the HPV vaccine worldwide	M. Kane	USA

## PLENARY SESSION 3

Friday, 19 February

8:00 – 9:30 **HPV vaccines: current status of ongoing trials**

Chair: **S. Garland (Australia) / M. Stanley (UK)**

<b>Lecture</b>	Reviewing the status of HPV vaccination to the critical issues	M. Stanley	UK
	<ul style="list-style-type: none"><li>• Insights from the trials of HPV vaccination</li><li>• What have we learned about the cross-type protection of HPV vaccines?</li><li>• Head to head immunogenicity trial: update results</li><li>• Cost effectiveness of HPV vaccines: a global perspective</li></ul>	J. Schiller C. Wheeler M. Einstein M. Brisson	USA USA USA Canada

## PLENARY SESSION 4

Friday, 19 February

9:30 – 11:00 **Building a strategy for primary and secondary prevention**

Chair: **J. Cuzick (UK) / T. Cox (USA)**

<b>Lecture</b>	<ul style="list-style-type: none"><li>• Overview of trials of HPV testing in primary screening</li><li>• Implementation of HPV testing in the Netherlands</li><li>• Is co-testing a viable screening strategy for the US?</li><li>• mRNA testing: the FASE Study</li><li>• Role of p16 and other cell cycle markers in triage</li><li>• How can professional guidelines on cervical cancer screening incorporate HPV testing?</li><li>• Cost-effectiveness of combined screening and vaccination interventions</li></ul>	E. Franco C. Meijer W. Kinney J. Monsonego F. Carrozzi T. Cox H. Berkhof	Canada Netherlands USA France Italy USA Netherlands
----------------	--	--	---

## PLENARY SESSION 5

Saturday, 20 February

8:00 – 9:15 **Post-vaccination experience - Implementation, monitoring, and safety issues**

Chair: **J. Dillner (Sweden) / H. Lawson (USA)**

<b>Lecture</b>	<ul style="list-style-type: none"><li>• HPV vaccination at the population level: Expected outcomes</li><li>• Monitoring the impact of HPV vaccination</li><li>• Overcoming barriers: how to improve the situation</li><li>• Safety issues: WHO initiatives</li><li>• Advocacy issues</li></ul>	S. Garland J. Dillner H. Lawson A. Caric S. Wittet	Australia Sweden USA Switzerland USA
----------------	--	--	--

## PLENARY SESSION 6

Saturday, 20 February

9:15 – 10:15 **Roadmap EUROGIN 2010**  
**Policy on cervical cancer prevention strategies:  
vaccination and screening**

Chair: C. Wheeler (USA) / S. Franceschi (France)

- |   |               |              |
|---|---------------|--------------|
| • Screening in high-resource countries                    | G. Ronco      | Italy        |
|   | P. Sasieni    | UK           |
| • Screening in intermediate- and low-resource countries   | L. Denny      | South Africa |
|   | J. Jeronimo   | USA          |
| • Vaccination in high-resource countries                  | L. Markowitz* | USA          |
|   | P. Lopalco    | Sweden       |
| • Vaccination in intermediate- and low-resource countries | K. Irwin      | USA          |
|   | J. Peto       | UK           |
| • Conclusions   | C. Wheeler    | USA          |
|   | S. Franceschi | France       |

## PLENARY SESSION 7

Saturday, 20 February

10:15 – 11:15 **Second generation of HPV vaccines and promising  
new preventive strategies**

Chair: J. Schiller (USA) / L. Gissmann (Germany)

- |   |              |             |
|---|--------------|-------------|
| • L2 vaccination  | R. Roden     | USA         |
| • Long E6/E7 therapeutic vaccine clinical trials                                      | K. Melief    | Netherlands |
| • rAAV as vectors for HPV immunization  | K. Nieto     | Germany     |
| • Intravaginal application of immune response modifiers<br>after systemic vaccination | L. Decrausaz | Switzerland |

## PLENARY SESSION 8

Saturday, 20 February

11:15 – 12:30 **Recent advances and major gaps in HPV research**

Chair: P. Castle (USA) / E. Franco (Canada)

- |  |               |         |
|--|---------------|---------|
| • An overview of HPV testing technologies  | C. Ginocchio  | USA     |
| • Immunology of HPV: gaps in knowledge and needed<br>research directions         | L. Gissmann   | Germany |
| • HPV biology: gaps in knowledge and needed research<br>directions               | F. Thierry    | France  |
| • HPV epidemiology: gaps in knowledge and needed<br>research directions          | S. Franceschi | France  |
| • HPV screening and testing: gaps in knowledge and<br>needed research directions | J. Cuzick     | UK      |
| • HPV vaccine: gaps in knowledge and needed research<br>directions               | J. Schiller   | USA     |
-

# TRANSLATIONAL SESSIONS (BASIC SCIENCE TO CLINICAL PRACTICE)

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

## Thursday, 18 February

### 14:00 – 15:30 **CS 01 – Management of abnormal Pap revisited** Chair: W. Kinney (USA) / W. Prendiville (Ireland)

- |  |  |          |         |             |             |              |     |             |         |        |     |
|--|--|----------|---------|-------------|-------------|--------------|-----|-------------|---------|--------|-----|
| <ul style="list-style-type: none"> <li>• - by age</li> <li>• - by HPV profile</li> <li>• - by colposcopic findings</li> <li>• - by risk factors</li> <li>• - by lesions: glandular lesions vs SIL</li> </ul> | <table border="0"> <tr><td>M. Arbyn</td><td>Belgium</td></tr> <tr><td>D. Rijkaart</td><td>Netherlands</td></tr> <tr><td>R. Pretorius</td><td>USA</td></tr> <tr><td>K. Syrjänen</td><td>Finland</td></tr> <tr><td>T. Cox</td><td>USA</td></tr> </table> | M. Arbyn | Belgium | D. Rijkaart | Netherlands | R. Pretorius | USA | K. Syrjänen | Finland | T. Cox | USA |
| M. Arbyn   | Belgium  |          |         |             |             |              |     |             |         |        |     |
| D. Rijkaart  | Netherlands  |          |         |             |             |              |     |             |         |        |     |
| R. Pretorius   | USA  |          |         |             |             |              |     |             |         |        |     |
| K. Syrjänen  | Finland  |          |         |             |             |              |     |             |         |        |     |
| T. Cox   | USA  |          |         |             |             |              |     |             |         |        |     |

## Friday, 19 February

### 8:00 – 9:15 **CS 02 – Colposcopy – Case studies** Chair: A. Ferenczy (Canada) / A. Singer (UK)

- |  |  |           |    |            |         |            |     |           |       |              |    |
|--|--|-----------|----|------------|---------|------------|-----|-----------|-------|--------------|----|
| <ul style="list-style-type: none"> <li>• The difficulty of assessing early invasive cancer</li> <li>• Pre-cancer in pregnancy</li> <li>• Pre-cancer differential diagnosis</li> <li>• Vaginal lesions</li> <li>• The HPV story: communicating key messages to a large public audience</li> </ul> | <table border="0"> <tr><td>A. Singer</td><td>UK</td></tr> <tr><td>K.U. Petry</td><td>Germany</td></tr> <tr><td>R. Cestero</td><td>USA</td></tr> <tr><td>M. Sideri</td><td>Italy</td></tr> <tr><td>A. Szarewski</td><td>UK</td></tr> </table> | A. Singer | UK | K.U. Petry | Germany | R. Cestero | USA | M. Sideri | Italy | A. Szarewski | UK |
| A. Singer  | UK   |           |    |            |         |            |     |           |       |              |    |
| K.U. Petry   | Germany  |           |    |            |         |            |     |           |       |              |    |
| R. Cestero   | USA  |           |    |            |         |            |     |           |       |              |    |
| M. Sideri  | Italy  |           |    |            |         |            |     |           |       |              |    |
| A. Szarewski   | UK   |           |    |            |         |            |     |           |       |              |    |

## Friday, 19 February

### 9:15 – 10:15 **CS 03 – Vulvar diseases - Case studies** Chair: R. Jones (New Zealand) / M. Roy (Canada)

- |  |  |        |        |             |        |          |             |              |        |                   |        |
|--|--|--------|--------|-------------|--------|----------|-------------|--------------|--------|-------------------|--------|
| <ul style="list-style-type: none"> <li>• Warts and mimics</li> <li>• Infectious diseases</li> <li>• VIN</li> <li>• Vulvar vestibulitis</li> <li>• Vulvar dermatosis</li> </ul> | <table border="0"> <tr><td>M. Roy</td><td>Canada</td></tr> <tr><td>C. Bouchard</td><td>Canada</td></tr> <tr><td>R. Jones</td><td>New Zealand</td></tr> <tr><td>J. Bornstein</td><td>Israel</td></tr> <tr><td>M. Moyal-Barracco</td><td>France</td></tr> </table> | M. Roy | Canada | C. Bouchard | Canada | R. Jones | New Zealand | J. Bornstein | Israel | M. Moyal-Barracco | France |
| M. Roy   | Canada   |        |        |             |        |          |             |              |        |                   |        |
| C. Bouchard  | Canada   |        |        |             |        |          |             |              |        |                   |        |
| R. Jones   | New Zealand  |        |        |             |        |          |             |              |        |                   |        |
| J. Bornstein   | Israel   |        |        |             |        |          |             |              |        |                   |        |
| M. Moyal-Barracco  | France   |        |        |             |        |          |             |              |        |                   |        |

## Saturday, 20 February

### 8:00 – 9:30 **CS 04 – Vaccines - Case studies** Chair: E. Joura (Austria) / P. Simon (Belgium)

- |   |   |          |         |         |     |          |         |             |     |               |     |
|---|---|----------|---------|---------|-----|----------|---------|-------------|-----|---------------|-----|
| <ul style="list-style-type: none"> <li>• Patients with current or past history of CIN</li> <li>• The mild-adult sexually active women</li> <li>• The male partner of SIL-positive woman</li> <li>• MSM's</li> <li>• Managing adverse events in teens</li> </ul> | <table border="0"> <tr><td>E. Joura</td><td>Austria</td></tr> <tr><td>K. Ault</td><td>USA</td></tr> <tr><td>P. Simon</td><td>Belgium</td></tr> <tr><td>J. Palefsky</td><td>USA</td></tr> <tr><td>A.B. Moscicki</td><td>USA</td></tr> </table> | E. Joura | Austria | K. Ault | USA | P. Simon | Belgium | J. Palefsky | USA | A.B. Moscicki | USA |
| E. Joura  | Austria   |          |         |         |     |          |         |             |     |               |     |
| K. Ault   | USA   |          |         |         |     |          |         |             |     |               |     |
| P. Simon  | Belgium   |          |         |         |     |          |         |             |     |               |     |
| J. Palefsky   | USA   |          |         |         |     |          |         |             |     |               |     |
| A.B. Moscicki   | USA   |          |         |         |     |          |         |             |     |               |     |

## Saturday, 20 February

### 9:30 – 11:00 CS 05 – HPV associated diseases in special situations

Chair: J. Palefsky (USA) / D. Harper (USA)

- |                           |                 |         |
|---------------------------|-----------------|---------|
| • Pregnancy               | E. Diakomanolis | Greece  |
| • HIV / Immunosuppression | I. Heard        | France  |
| • Menopause               | K.U. Petry      | Germany |
| • Teenagers               | A.B. Moscicki   | USA     |
| • Men                     | A. Giuliano     | USA     |

---

## DEBATES ON CONTROVERSIAL ISSUES

The programme of these sessions is specially planned to engaged in controversial issues as a meeting forum for world experts. They are also designed to be a forum for discussion among peer experts and participants whose questions arise from the lack of evidence and which to achieve consensus based on expert opinions.

## Thursday, 18 February

### 15:30 – 17:00 DE1 - Vaccination

Chair: J. Paavonen (Finland) / M. Stanley (UK)

- |  |               |         |
|--|---------------|---------|
| • Alternative vaccine schedules: yes or no?                | K. Irwin      | USA     |
| • Catch-up vaccination: yes or no?                         | M. Steben     | Canada  |
| • Vaccination of males: yes or no?                         | E. Joura      | Austria |
| • Adult vaccination: yes or no?                            | M. Arbyn      | Belgium |
| • Is type replacement something to worry about: yes or no? | A. Giuliano   | USA     |
|  | C. Wheeler    | USA     |
|  | D. Harper     | USA     |
|  | S. Franceschi | France  |
|  | E. Franco     | Canada  |
|  | J. Dillner    | Sweden  |

## Friday, 19 February

### 10:15 – 11:15 DE2 - Screening

Chair: C. Meijer (Netherlands) / T. Cox (USA)

- |   |               |             |
|---|---------------|-------------|
| • HPV screening: alone or combined with cytology  | J. Cuzick     | UK          |
| • HPV testing: which test is the best choice of HPV testing technology for clinical practice? | T. Cox        | USA         |
| • Screening in young adult: is it necessary?  | P. Castle     | USA         |
| • Best screening program for vaccinated women   | T. Iftner     | Germany     |
|   | P. Sasieni    | UK          |
|   | W. Kinney     | USA         |
|   | V. Coupe      | Netherlands |
|   | S. de Sanjose | Spain       |

## Saturday, 20 February

<b>11:00 – 12:30</b>	<b>DE3 - Management</b> <b>Chair: M. Sideri (Italy) / S. Dexeus (Spain)</b>		
	<ul style="list-style-type: none"><li>Genital warts: ablation vs. conservative therapies</li></ul>	G. Gross A. Ferenczy	Germany Canada
	<ul style="list-style-type: none"><li>CIN2 what is it?</li></ul>	W. Prendiville M. Stoler	Ireland USA
	<ul style="list-style-type: none"><li>Cervical cancer and fertility conservation in young women: yes or no?</li></ul>	M. Roy P. Morice	Canada France
	<ul style="list-style-type: none"><li>Assessing risk profile: is it of value in clinical practice?</li></ul>	N. Wentzensen K. Syrjänen	USA Finland
	<ul style="list-style-type: none"><li>Medicolegal controversies</li></ul>	M. Sideri R. Kurman	Italy USA

---

# WORKSHOPS

## MEET INTERNATIONAL HEALTH ORGANIZATIONS

The workshops are designed to meet leaders who serve international organizations involved in cervical cancer prevention.

These sessions enable the participants to share their experience with the experts and to better understand the missions, activities, experiences and perspectives of your organization programme.

## Wednesday – 17 February

<b>8:30 – 9:30</b>	<b>WS1 – Cervical cancer control in the developing world (GAVI)</b> <b>Chair: M. Kane (USA)</b>		
<b>9:30 – 10:30</b>	<b>WS2 - WHO / IARC</b> <b>Chair: S. Franceschi (France) /</b>		
	<ul style="list-style-type: none"><li>The WHO policy on HPV vaccine use in national immunization programs</li></ul>	K. Irwin	USA
<b>10:30 – 11:30</b>	<b>WS3 - PATH</b> <b>Chair: J. Jeronimo (USA) / S. Wittet (USA)</b>		
<b>11:30 - 12:30</b>	<b>WS4 - IFCPC - EFC</b> <b>Chair: W. Prendiville (Ireland) / S. Tatti (Argentina)</b>		
<b>14:00 – 15:00</b>	<b>WS5 - WACC</b> <b>Chair: S. Pecorelli (Italy) / P. Morton (Ireland)</b>		
<b>15:00– 16:00</b>	<b>WS6 - CDC / NCI</b> <b>Chair: P. Castle (USA) / H. Lawson (USA)</b>		
<b>16:00 – 17:00</b>	<b>WS7 - ECDC</b> <b>Chair: P. Lopalco (Sweden)</b>		
	<ul style="list-style-type: none"><li>VENICE initiative</li></ul>	D. Levy-Bruhl	France



---

# **SCIENTIFIC SESSIONS**

These concurrent sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to HPV research, cancer screening prevention and management of patients with HPV-associated diseases. Each presentation should not exceed 8 minutes which leaves 2 minutes for discussion.

## **Thursday – 18 February**

**8:00 – HPV testing I (9 presentations)**  
**9:30 Chair: H. Cubie (UK) / T. Iftner (Germany)**

**9:30 – Genotyping (9 presentations)**  
**11:00 Chair: P. Castle (USA) / G. Clifford (France)**

## **Friday – 19 February**

**8:00 – Low resource settings (9 presentations)**  
**9:30 Chair: J. Jeronimo (USA) / L. Denny (South Africa)**

**14:00 – Vaccines: emerging issues (9 presentations)**  
**15:30 Chair: C. Wheeler (USA) / J. Paavonen (Finland)**

**16:00 – Vaccines: research and development (9 presentations)**  
**17:30 Chair: P. Coursaget (France) / A. Giuliano (USA)**

**17:30 – Vaccines (9 presentations)**  
**19:00 Chair: K. Irwin (USA) / P. Simon (Belgium)**

**14:00 – Management of CIN (9 presentations)**  
**15:30 Chair: W. Prendiville (Ireland) / J. Cortes (Spain)**

**16:00 – Screening (9 presentations)**  
**17:30 Chair: M. Van Ballegooijen (Netherlands) / G. Ronco (Italy)**

**14:00 – HPV testing II (9 presentations)**  
**15:30 Chair: P. Snijders (Netherlands) / C. Clavel (France)**

**16:00 – Molecular markers (9 presentations)**  
**17:30 Chair: K. Syrjänen (Finland) / J. Doorbar (UK)**

**14:00 – Immunology (9 presentations)**  
**15:30 Chair: M. Pawlita (Germany) / P. Stern (UK)**

**16:00 – The role of screening and pathology in the vaccine era (9 presentations)**  
**17:30 Chair: R. Kurman (USA) / E. Mc Googan (UK)**

**14:00 – Epidemiology I: Natural history – HPV and associated diseases, highlights from the vaccine trials**  
**15:30 Chair: J. Smith (USA) / X. Castellsagué (Spain)**

16:00 – **Epidemiology II – HPV infection (9 presentations)**  
17:30 Chair: S. Kjaer (Denmark) / H. Trottier (Canada)

14:00 – **HPV related diseases- Quality of life (9 presentations)**  
15:30 Chair:

16:00 – **Gynecological cancers: recent progress in the management**  
17:30 Chair: S. Dexeus (Spain) / M. Roy (Canada)

## **Saturday – 20 February**

12:30 – **Advocacy – societal and ethical issues**  
14:00 (9 presentations)  
Chair: D. Harper (USA) / A. Szarewski (UK)

8:00 –  
9:30 **HPV associated diseases in males (9 presentations)**  
Chair: M. Steben (Canada) / G. Gross (Germany)

9:30 – **Non cervical sites (9 presentations)**  
11:00 Chair: S. Syrjänen (Finland) / S. Franceschi (France)

8:00 – **HPV screening (9 presentations)**  
9:30 Chair: K. Cuschieri (UK) / M. Arbyn (Belgium)

9:30 – **Health economics (9 presentations)**  
11:00 Chair: M. Brisson (Canada) / H. Berkhof (Netherlands)

11:00 – **Health education (9 presentations)**  
12:30 Chair: S. Pecorelli (Italy) / J.C. Boulanger (France)

8:00 – **New technologies (9 presentations)**  
9:30 Chair: E. Diakomanolis (Greece) / J.L. Mergui (France)

9:30 – **Molecular biology (9 presentations)**  
11:00 Chair: J.P. Bogers (Belgium) / M. Von Knebel-Doeberitz (Germany)

11:00 – **Epidemiology III (9 presentations)**  
12:30 Chair: S. De Sanjose Llongueras (Spain) / C. Mouglin (France)

---

## **FREE COMMUNICATIONS**

The organizing committee welcomes the presentation of proffered papers, with preference being given to original papers on unpublished findings of broad interest. Abstracts presented must comply with the conditions which will be set out in the "Abstract Submission Conditions" which will soon be posted on the EUROGIN website.

The abstract submission deadline is September 15, 2009. Submitted papers will be reviewed by the scientific committee.